Stem cell banking is the process of collecting, processing and storing of stem cells, commonly from umbilical cord blood and tissue for future use in transplantation and research activities. Stem cells present in umbilical cord blood offer advantages like lower risk of transmitting infections, higher proliferation potential, and ability to treat a wider range of blood and immune disorders. Cord blood is collected from the umbilical cord and placenta after birth and the stem cells within are isolated and cryogenically frozen and stored in specialized stem cell banks for future medical need.

The global stem cell banking market size was valued at US$ 616.11 Mn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period 2024 -2030.

Key players operating in the stem cell banking market are CM Fine Chemicals GmbH, Hawks Chemical Company, Hebei Yingong New Material Technology Co., Ltd., Heranba Industries Ltd., Jiangsu Dacheng Pharmaceutical and Chemical Co., Ltd., Luyunjia Chemistry Xiamen Limited, Merck KGaA, Mody Chemi-Pharma Limited, RX MARINE INTERNATIONAL, and Yancheng Longsheng Chemical Co., Ltd. The growing prevalence of blood disorders and genetic diseases as well as rising awareness about stem cell therapies is fuelling the demand for cord blood banking services globally. Furthermore, advancements in stem cell therapies are projected to enhance treatment outcomes which will also accelerate the market growth.

Key Takeaways:

Key players operating in the Global Stem Cell Banking Market Share are focusing on acquisition and regional expansion strategies to consolidate their market share. CM Fine Chemicals GmbH acquired a leading stem cell bank in 2022 to expand its storage capacities.

The growing demand for treatment of blood disorders such as leukemia, thalassemia and metabolic diseases is driving individuals to opt for stem cell banking services. Nearly 1 million stem cell transplants have been performed globally according to World Marrow Donor Association.

North America dominates the global stem cell banking market owing to increasing usage of these cells in disease treatment and presence of supportive government regulations regarding cord blood banking. However, Asia Pacific market is expected to witness highest CAGR during the forecast period with expanding healthcare infrastructure and increasing healthcare expenditure in countries like China and India.

Market drivers:

Rising prevalence of chronic diseases is a key factor propelling the demand for umbilical cord blood storage globally. Diseases such as cancer, blood disorders may require stem cell transplant procedures in future. As per WHO, around 10 million new cancer cases emerge yearly worldwide.

Growing awareness about the therapeutic benefits of umbilical cord stem cells and established medical reimbursements for private cord blood banking in developed nations are positively impacting the market growth. Additionally, increasing R&D investments by pharmaceutical companies in developing stem cell therapies will continue driving the stem cell banking industry during the forecast period.

The current geopolitical uncertainties have impacted the growth of the stem cell banking market. The conflict between Russia and Ukraine has disrupted supply chains and created instability in Europe. As medical tourism and stem cell collection from umbilical cord blood has reduced between these nations, market players have faced challenges. Companies operating in this region are exploring strategic partnerships and investing in automation to minimize disruptions. While outsourcing of non-core functions can help offset short term impacts, long term strategies will need to focus on developing local stem cell collection capabilities and infrastructure in multiple regions to reduce overdependence on single regions and countries. Boosting domestic capabilities will help insulate the market from external political and economic shocks in the future.

North America holds the largest share of the stem cell banking market in terms of value currently. This is attributed to favorable regulatory environment and increasing initiatives by both public and private organizations to spread awareness about stem cell therapy and banking. However, Asia Pacific region is projected to grow at the fastest rate during the forecast period. Increasing healthcare expenditure, rising awareness about stem cell therapies, and supportive government initiatives in countries like China and India are some major factors driving regional market growth. Coupled with growing medical tourism industry, Asia Pacific offers immense opportunities for stem cell banking market players in the coming years.

The United States currently accounts for over 35% of the global stem cell banking market value and is the largest regional market. High clinical research activity, widespread healthcare infrastructure, availability of private and public banking facilities and supportive regulatory framework have boosted market growth. However, China is expected to surpass the US and become the leading stem cell banking market in the world by 2028 given its increasing healthcare investments, large patient pool for diseases treatable by stem cells, and government thrust on indigenous research. Growing penetration of commercial and public banking facilities along with strengthening of regulatory guidelines will fuel further expansion of the stem cell banking industry in China and other Asian nations going forward.

Get More Insights Here

https://www.newsanalyticspro.com/stem-cell-banking-market-size-share-growth-outlook-2023/